Jim Scibetta Named CEO of VectorY Therapeutics
Jim Scibetta appointed CEO at VectorY, leading ALS therapy VTx-002 into clinical trials by 2025.
VectorY Therapeutics has named Jim Scibetta as CEO, with founder Sander van Deventer transitioning to President of R&D. Scibetta, known for leading biotech innovations, will drive the clinical advancement of VTx-002, a promising vectorized antibody targeting TDP-43 for ALS, aiming to enter trials by 2025.
VectorY recently secured $138 million in Series A funding to develop its pipeline and has expanded to Boston. The company’s platform seeks to address neurodegenerative diseases by targeting underlying disease drivers, with VTx-002 positioned to preserve quality of life in ALS patients.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix
Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park
Discussion